EEF2K and acute myeloid leukemia: Phosphoproteomic analysis of untreated AML cell lines identified several eEF2K activity markers (including p-eEF2 at T57/T59 and its autophosphorylation site S455) as a potential signature to predict responses to dual PI3Ki + MEKi treatment (Fig. 6).